Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L F Wymenga

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
BJU International|August 8, 2001
Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphataseL F Wymenga, J H Boomsma, K Groenier, et al.
European Journal of Clinical Investigation|April 12, 2000
Telomerase activity in needle biopsies from prostate cancer and benign prostatesL F Wymenga, G B Wisman, R Veenstra, et al.
BJU International|August 8, 2001
Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasisL F Wymenga, K Groenier, J Schuurman, et al.
Scandinavian Journal of Urology and Nephrology|August 29, 2000
Clinical implications of free-to-total immunoreactive prostate-specific antigen ratiosL F Wymenga, F J Duisterwinkel, K Groenier, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
BJU International|August 8, 2001
Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphataseL F Wymenga, J H Boomsma, K Groenier, et al.
European Journal of Clinical Investigation|April 12, 2000
Telomerase activity in needle biopsies from prostate cancer and benign prostatesL F Wymenga, G B Wisman, R Veenstra, et al.
BJU International|August 8, 2001
Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasisL F Wymenga, K Groenier, J Schuurman, et al.
Scandinavian Journal of Urology and Nephrology|August 29, 2000
Clinical implications of free-to-total immunoreactive prostate-specific antigen ratiosL F Wymenga, F J Duisterwinkel, K Groenier, et al.
Pageof 2